ArticleCancers2022

Time-Dependent Efficacy of Checkpoint Inhibitor Nivolumab: Results from a Pilot Study in Patients with Metastatic Non-Small-Cell Lung Cancer.

Abdoulaye Karaboué et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.